Comparison of pre-and postoperative medication costs in patients who underwent bariatric surgery - a nationwide data analysis

Bariatric surgery has known health benefits and may lower the medication-related costs. This study aimed to assess the cost of medications prior to and after bariatric surgery in the Polish nationwide registry. The study included 2,390 adults. The analysis was conducted separately for a 12-month pre...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in public health Vol. 12; p. 1344040
Main Authors: Osińska, Magdalena, Sanchak, Yaroslav, Śliwczyński, Andrzej, Franek, Edward, Walicka, Magdalena
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 08-02-2024
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bariatric surgery has known health benefits and may lower the medication-related costs. This study aimed to assess the cost of medications prior to and after bariatric surgery in the Polish nationwide registry. The study included 2,390 adults. The analysis was conducted separately for a 12-month pre-operative period, and a 12-month postoperative period. The total costs of medication and cost per anatomical therapeutic chemical group were assessed and the mean cost per patient in the preoperative and postoperative periods was compared. The study showed a significant increase in the overall medication costs and mean costs of medications per patient in the year after bariatric surgery. This increase was related mainly to low-molecular-weight heparins used in the 1st month after surgery. Alternatively, costs of medication used in the cardiovascular system diseases and anti-infectives decreased significantly. The total costs of hypoglycemic agents were reduced by 46%, antihypertensive medications by 29%, and lipid-lowering drugs by 38. In general, medication costs are higher in the first year after surgery. The increase results from the perioperative use of low-molecular-weight heparins, whereas a significant cost reduction of glucose-, lipid-lowering, antihypertensive, and anti-infective medications was observed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Sabrina Oussaada, Academic Medical Center, Netherlands
Reviewed by: Małgorzata Kowalska, Medical University of Silesia, Poland
Edited by: Domenica Matranga, University of Palermo, Italy
ISSN:2296-2565
2296-2565
DOI:10.3389/fpubh.2024.1344040